Mural Oncology plc (NASDAQ: MURA)’s stock price has increased by 185.44 compared to its previous closing price of 1.03. However, the company has seen a 169.72% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-15 that Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 15, 2025 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, today announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the company is discontinuing all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value.
Is It Worth Investing in Mural Oncology plc (NASDAQ: MURA) Right Now?
Additionally, the 36-month beta value for MURA is 5.07. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for MURA is 15.34M and currently, short sellers hold a 3.88% ratio of that float. The average trading volume of MURA on April 15, 2025 was 271.51K shares.
MURA’s Market Performance
MURA stock saw a decrease of 169.72% in the past week, with a monthly decline of -27.76% and a quarterly a decrease of -20.97%. The volatility ratio for the week is 13.28%, and the volatility levels for the last 30 days are 12.56% for Mural Oncology plc (MURA). The simple moving average for the last 20 days is 60.94% for MURA stock, with a simple moving average of -12.27% for the last 200 days.
Analysts’ Opinion of MURA
Many brokerage firms have already submitted their reports for MURA stocks, with Raymond James repeating the rating for MURA by listing it as a “Outperform.” The predicted price for MURA in the upcoming period, according to Raymond James is $18 based on the research report published on March 25, 2025 of the current year 2025.
Rodman & Renshaw gave a rating of “Buy” to MURA, setting the target price at $15 in the report published on June 28th of the previous year.
MURA Trading at -4.89% from the 50-Day Moving Average
After a stumble in the market that brought MURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.97% of loss for the given period.
Volatility was left at 12.56%, however, over the last 30 days, the volatility rate increased by 13.28%, as shares sank -34.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.04% lower at present.
During the last 5 trading sessions, MURA rose by +155.05%, which changed the moving average for the period of 200-days by -9.45% in comparison to the 20-day moving average, which settled at $1.8190. In addition, Mural Oncology plc saw -8.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MURA starting from Loew Caroline, who proposed sale 4,313 shares at the price of $3.36 back on Mar 04 ’25. After this action, Loew Caroline now owns shares of Mural Oncology plc, valued at $14,491 using the latest closing price.
Keson-Brookes Maiken, the of Mural Oncology plc, sale 1,469 shares at $3.45 during a trade that took place back on Mar 05 ’25, which means that Keson-Brookes Maiken is holding 73,564 shares at $5,068 based on the most recent closing price.
Stock Fundamentals for MURA
The total capital return value is set at -0.97. Equity return is now at value -63.57, with -54.55 for asset returns.
Based on Mural Oncology plc (MURA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -16.02.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.83.
Conclusion
In conclusion, Mural Oncology plc (MURA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
